Coronavirus Stocks Are Zooming Higher Today_老虎社区_美港股上老虎

Coronavirus Stocks Are Zooming Higher Today

Motley Fool2021-07-20

The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20) Coronavirus Stocks Are Zooming Higher Today. So what The key reason ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

302

SK118
·2021-08-10
Upupup
回复
点赞
举报
GG21
·2021-07-24
[Grin]
回复
3
举报
收起
- GG21:
  [Happy]
  2021-07-25
  回复
  举报
Yangli
·2021-07-21
Looking good so far
回复
6
举报
Pangabui
·2021-07-21
[白眼] [白眼] [微笑]
回复
5
举报
Gee1
·2021-07-21
trending high
回复
7
举报
AndrewL
·2021-07-21
Looks promising!
回复
6
举报
收起
- Gee1:
  well done
  2021-07-21
  回复
  举报
JFK
·2021-07-21
Pls like
回复
4
举报
收起
- 一支升GoGo:
  👍
  2021-07-22
  回复
  举报
Kervin21
·2021-07-21
Like and comment pls
回复
1
举报
收起
- JeremyKok:
  hi. please like and comment back. thank you.
  2021-07-21
  回复
  举报
- Kervin21:
  👍🏻
  2021-07-21
  回复
  举报
- buckethead:
  ok done
  2021-07-21
  回复
  举报
jacksoncheng
·2021-07-21
Yeah, it is ridiculous to see moderna getting new high
回复
3
举报
收起
- jacksoncheng:
  hhhh
  2021-12-26
  回复
  举报
- Nickystonks:
  agree
  2021-07-21
  回复
  举报
- jacksoncheng:
  no way I don't like it
  2021-07-24
  回复
  举报
查看更多 1 条评论
EeHoe
·2021-07-21
hopefully will covid will pass soon.
回复
1
举报
收起
- sk5735:
  Yup :(
  2021-07-21
  回复
  举报
andrew123
·2021-07-21
Looks like tourism sector stk will be in for a hard time for recovery. Like n comment
回复
4
举报
收起
- EeHoe:
  yaa
  2021-07-21
  回复
  举报
- JeremyKok:
  hi. please like and comment back. thank you.
  2021-07-21
  回复
  举报
- andrew123:
  done
  2021-07-21
  回复
  举报
查看更多 1 条评论
Huatkor
·2021-07-21
If the current vaccine can offer sufficient protection against the variants then their price shouldn’t surge so much.
回复
2
举报
在於我們是
·2021-07-21
Please like and comment [Grin]
回复
6
举报
收起
- andrew123:
  like yrs u like mine.ok
  2021-07-21
  回复
  举报
- JeremyKok:
  hi. please like and comment back. thank you.
  2021-07-21
  回复
  举报
Terc
·2021-07-21
Let's see
回复
5
举报
YKYANG
·2021-07-21
Good to buy
回复
2
举报
koolgal
·2021-07-21
I shall put on watch list.
回复
19
举报
收起
- 4e6e78ce:
  all the best!
  2021-07-21
  回复
  举报
- 56a3dd2f:
  😊👍
  2021-07-21
  回复
  举报
- koolgal:
  Thanks
  2021-07-21
  回复
  举报
查看更多 1 条评论
飞天神鼠
·2021-07-21
[财迷] [财迷]
回复
5
举报
SPOT_ON
·2021-07-21
Like n follow
回复
4
举报
收起
- JeremyKok:
  hi. please like and comment back. thank you.
  2021-07-21
  回复
  举报
KevinToh
·2021-07-21
Nice
回复
2
举报
7a1f5064
·2021-07-21
All pharma going up
回复
3
举报

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1199016731?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-07-20 22:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199016731","market":"us","top_or_hot":-1,"title":"Coronavirus Stocks Are Zooming Higher Today","media":"Motley Fool","content":"<div>\nThe surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.\n\n(July 20) Coronavirus Stocks Are Zooming Higher Today.\n\nSo what\nThe key reason ...\n\n<a href=\"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">网页链接</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coronavirus Stocks Are Zooming Higher Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoronavirus Stocks Are Zooming Higher Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-20 22:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nThe surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.\n\n(July 20) Coronavirus Stocks Are Zooming Higher Today.\n\nSo what\nThe key reason ...\n\n<a href=\"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PFE","symbol_name":"辉瑞","start_time":0,"source_url":"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","article_id":"1199016731","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199016731","pubTimestamp":1626790980,"columns":[],"sourceInfo":null,"weMediaInfo":null,"summary":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and p","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PFE":"辉瑞","CVAC":"CureVac B.V.","MRK":"默沙东","AZN":"阿斯利康","JNJ":"强生","MRNA":"Moderna, Inc.","SNY":"赛诺菲安万特","NVAX":"诺瓦瓦克斯医药","GSK":"葛兰素史克","BNTX":"BioNTech SE"},"translate_title":"冠状病毒股票今天飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":0.9,"NVAX":0.9,"MRK":0.9,"BNTX":0.9,"AZN":0.9,"MRNA":0.9,"GSK":0.9,"SNY":0.9,"CVAC":0.9,"JNJ":0.9},"content_text":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.\n\n(July 20) Coronavirus Stocks Are Zooming Higher Today.\n\nSo what\nThe key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.\nSo the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.\nNow what\nIf the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.\nNovavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.","kind":"news","is_publish_news":false,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":896700642,"gmtCreate":1628603735686,"gmtModify":1631889824885,"author":{"id":"3577519492325313","authorId":"3577519492325313","name":"SK118","avatar":"https://static.tigerbbs.com/9a303d951cd8f8b608ce003cd75d133a","vip":1,"crmLevel":12,"crmLevelSwitch":0,"idStr":"3577519492325313","authorIdStr":"3577519492325313"},"htmlText":"Upupup","listText":"Upupup","text":"Upupup","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/896700642","repostId":1199016731,"repostType":2,"repost":{"id":"1199016731","kind":"news","pubTimestamp":1626790980,"share":"https://www.laohu8.com/m/news/1199016731?lang=zh_CN&edition=full","pubTime":"2021-07-20 22:23","market":"us","language":"en","title":"Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1199016731","media":"Motley Fool","summary":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and p","content":" The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-07-20 22:23\n\n</h4>\n</header>\n<article>\n The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","CVAC":"CureVac B.V.","MRK":"默沙东","AZN":"阿斯利康","JNJ":"强生","MRNA":"Moderna, Inc.","SNY":"赛诺菲安万特","NVAX":"诺瓦瓦克斯医药","GSK":"葛兰素史克","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199016731","content_text":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.\n\n(July 20) Coronavirus Stocks Are Zooming Higher Today.\n\nSo what\nThe key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.\nSo the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.\nNow what\nIf the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.\nNovavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.","news_type":1,"symbols_score_info":{"PFE":0.9,"NVAX":0.9,"MRK":0.9,"BNTX":0.9,"AZN":0.9,"MRNA":0.9,"GSK":0.9,"SNY":0.9,"CVAC":0.9,"JNJ":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":174476421,"gmtCreate":1627133937363,"gmtModify":1633767728342,"author":{"id":"3578365762999468","authorId":"3578365762999468","name":"GG21","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":12,"crmLevelSwitch":0,"idStr":"3578365762999468","authorIdStr":"3578365762999468"},"htmlText":"[Grin]&nbsp;","listText":"[Grin]&nbsp;","text":"[Grin]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/174476421","repostId":1199016731,"repostType":4,"repost":{"id":"1199016731","kind":"news","pubTimestamp":1626790980,"share":"https://www.laohu8.com/m/news/1199016731?lang=zh_CN&edition=full","pubTime":"2021-07-20 22:23","market":"us","language":"en","title":"Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1199016731","media":"Motley Fool","summary":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and p","content":" The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-07-20 22:23\n\n</h4>\n</header>\n<article>\n The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","CVAC":"CureVac B.V.","MRK":"默沙东","AZN":"阿斯利康","JNJ":"强生","MRNA":"Moderna, Inc.","SNY":"赛诺菲安万特","NVAX":"诺瓦瓦克斯医药","GSK":"葛兰素史克","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199016731","content_text":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.\n\n(July 20) Coronavirus Stocks Are Zooming Higher Today.\n\nSo what\nThe key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.\nSo the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.\nNow what\nIf the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.\nNovavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.","news_type":1,"symbols_score_info":{"PFE":0.9,"NVAX":0.9,"MRK":0.9,"BNTX":0.9,"AZN":0.9,"MRNA":0.9,"GSK":0.9,"SNY":0.9,"CVAC":0.9,"JNJ":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5320625,"gmtCreate":1627177139271,"gmtModify":1635222087593,"authorId":3578365762999468,"author":{"id":3578365762999468,"idStr":"3578365762999468","authorId":3578365762999468,"name":"GG21","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":174476421,"type":1,"supId":0,"prevId":0,"content":"[Happy]","text":"[Happy]","html":"[Happy]"}],"langContent":"EN"},{"id":176063400,"gmtCreate":1626846313200,"gmtModify":1631890990658,"author":{"id":"3579994912149905","authorId":"3579994912149905","name":"Yangli","avatar":"https://static.tigerbbs.com/25439208a5e1956d7369976afd67267e","vip":1,"crmLevel":12,"crmLevelSwitch":0,"idStr":"3579994912149905","authorIdStr":"3579994912149905"},"htmlText":"Looking good so far","listText":"Looking good so far","text":"Looking good so far","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/176063400","repostId":1199016731,"repostType":4,"repost":{"id":"1199016731","kind":"news","pubTimestamp":1626790980,"share":"https://www.laohu8.com/m/news/1199016731?lang=zh_CN&edition=full","pubTime":"2021-07-20 22:23","market":"us","language":"en","title":"Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1199016731","media":"Motley Fool","summary":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and p","content":" The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-07-20 22:23\n\n</h4>\n</header>\n<article>\n The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","CVAC":"CureVac B.V.","MRK":"默沙东","AZN":"阿斯利康","JNJ":"强生","MRNA":"Moderna, Inc.","SNY":"赛诺菲安万特","NVAX":"诺瓦瓦克斯医药","GSK":"葛兰素史克","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199016731","content_text":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.\n\n(July 20) Coronavirus Stocks Are Zooming Higher Today.\n\nSo what\nThe key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.\nSo the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.\nNow what\nIf the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.\nNovavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.","news_type":1,"symbols_score_info":{"PFE":0.9,"NVAX":0.9,"MRK":0.9,"BNTX":0.9,"AZN":0.9,"MRNA":0.9,"GSK":0.9,"SNY":0.9,"CVAC":0.9,"JNJ":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":178512137,"gmtCreate":1626827298729,"gmtModify":1633770676295,"author":{"id":"3570444284639989","authorId":"3570444284639989","name":"Pangabui","avatar":"https://static.tigerbbs.com/32b4b9242d9aab94ee79aaaf573818e8","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3570444284639989","authorIdStr":"3570444284639989"},"htmlText":"[白眼]&nbsp;[白眼]&nbsp;[微笑]&nbsp;","listText":"[白眼]&nbsp;[白眼]&nbsp;[微笑]&nbsp;","text":"[白眼] [白眼] [微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/178512137","repostId":1199016731,"repostType":4,"repost":{"id":"1199016731","kind":"news","pubTimestamp":1626790980,"share":"https://www.laohu8.com/m/news/1199016731?lang=zh_CN&edition=full","pubTime":"2021-07-20 22:23","market":"us","language":"en","title":"Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1199016731","media":"Motley Fool","summary":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and p","content":" The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-07-20 22:23\n\n</h4>\n</header>\n<article>\n The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","CVAC":"CureVac B.V.","MRK":"默沙东","AZN":"阿斯利康","JNJ":"强生","MRNA":"Moderna, Inc.","SNY":"赛诺菲安万特","NVAX":"诺瓦瓦克斯医药","GSK":"葛兰素史克","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199016731","content_text":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.\n\n(July 20) Coronavirus Stocks Are Zooming Higher Today.\n\nSo what\nThe key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.\nSo the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.\nNow what\nIf the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.\nNovavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.","news_type":1,"symbols_score_info":{"PFE":0.9,"NVAX":0.9,"MRK":0.9,"BNTX":0.9,"AZN":0.9,"MRNA":0.9,"GSK":0.9,"SNY":0.9,"CVAC":0.9,"JNJ":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":178279783,"gmtCreate":1626825623942,"gmtModify":1633770717264,"author":{"id":"3555136548043615","authorId":"3555136548043615","name":"Gee1","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3555136548043615","authorIdStr":"3555136548043615"},"htmlText":"trending high","listText":"trending high","text":"trending high","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/178279783","repostId":1199016731,"repostType":4,"repost":{"id":"1199016731","kind":"news","pubTimestamp":1626790980,"share":"https://www.laohu8.com/m/news/1199016731?lang=zh_CN&edition=full","pubTime":"2021-07-20 22:23","market":"us","language":"en","title":"Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1199016731","media":"Motley Fool","summary":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and p","content":" The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-07-20 22:23\n\n</h4>\n</header>\n<article>\n The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","CVAC":"CureVac B.V.","MRK":"默沙东","AZN":"阿斯利康","JNJ":"强生","MRNA":"Moderna, Inc.","SNY":"赛诺菲安万特","NVAX":"诺瓦瓦克斯医药","GSK":"葛兰素史克","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199016731","content_text":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.\n\n(July 20) Coronavirus Stocks Are Zooming Higher Today.\n\nSo what\nThe key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.\nSo the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.\nNow what\nIf the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.\nNovavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.","news_type":1,"symbols_score_info":{"PFE":0.9,"NVAX":0.9,"MRK":0.9,"BNTX":0.9,"AZN":0.9,"MRNA":0.9,"GSK":0.9,"SNY":0.9,"CVAC":0.9,"JNJ":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":178265757,"gmtCreate":1626824250279,"gmtModify":1633770747571,"author":{"id":"3571815908504020","authorId":"3571815908504020","name":"AndrewL","avatar":"https://static.tigerbbs.com/f45655eaaab14f0b61c554eea4d95ca7","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3571815908504020","authorIdStr":"3571815908504020"},"htmlText":"Looks promising!&nbsp;","listText":"Looks promising!&nbsp;","text":"Looks promising!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/178265757","repostId":1199016731,"repostType":4,"repost":{"id":"1199016731","kind":"news","pubTimestamp":1626790980,"share":"https://www.laohu8.com/m/news/1199016731?lang=zh_CN&edition=full","pubTime":"2021-07-20 22:23","market":"us","language":"en","title":"Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1199016731","media":"Motley Fool","summary":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and p","content":" The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-07-20 22:23\n\n</h4>\n</header>\n<article>\n The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","CVAC":"CureVac B.V.","MRK":"默沙东","AZN":"阿斯利康","JNJ":"强生","MRNA":"Moderna, Inc.","SNY":"赛诺菲安万特","NVAX":"诺瓦瓦克斯医药","GSK":"葛兰素史克","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199016731","content_text":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.\n\n(July 20) Coronavirus Stocks Are Zooming Higher Today.\n\nSo what\nThe key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.\nSo the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.\nNow what\nIf the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.\nNovavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.","news_type":1,"symbols_score_info":{"PFE":0.9,"NVAX":0.9,"MRK":0.9,"BNTX":0.9,"AZN":0.9,"MRNA":0.9,"GSK":0.9,"SNY":0.9,"CVAC":0.9,"JNJ":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5277353,"gmtCreate":1626825582731,"gmtModify":1631896008380,"authorId":3555136548043615,"author":{"id":3555136548043615,"idStr":"3555136548043615","authorId":3555136548043615,"name":"Gee1","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":178265757,"type":1,"supId":0,"prevId":0,"content":"well done","text":"well done","html":"well done"}],"langContent":"EN"},{"id":178234418,"gmtCreate":1626823106234,"gmtModify":1633770775160,"author":{"id":"3567221235003553","authorId":"3567221235003553","name":"JFK","avatar":"https://static.tigerbbs.com/d8cdaf8b81ae245f2f2ea5ff303a6722","vip":1,"crmLevel":12,"crmLevelSwitch":0,"idStr":"3567221235003553","authorIdStr":"3567221235003553"},"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/178234418","repostId":1199016731,"repostType":4,"repost":{"id":"1199016731","kind":"news","pubTimestamp":1626790980,"share":"https://www.laohu8.com/m/news/1199016731?lang=zh_CN&edition=full","pubTime":"2021-07-20 22:23","market":"us","language":"en","title":"Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1199016731","media":"Motley Fool","summary":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and p","content":" The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-07-20 22:23\n\n</h4>\n</header>\n<article>\n The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","CVAC":"CureVac B.V.","MRK":"默沙东","AZN":"阿斯利康","JNJ":"强生","MRNA":"Moderna, Inc.","SNY":"赛诺菲安万特","NVAX":"诺瓦瓦克斯医药","GSK":"葛兰素史克","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199016731","content_text":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.\n\n(July 20) Coronavirus Stocks Are Zooming Higher Today.\n\nSo what\nThe key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.\nSo the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.\nNow what\nIf the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.\nNovavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.","news_type":1,"symbols_score_info":{"PFE":0.9,"NVAX":0.9,"MRK":0.9,"BNTX":0.9,"AZN":0.9,"MRNA":0.9,"GSK":0.9,"SNY":0.9,"CVAC":0.9,"JNJ":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5288072,"gmtCreate":1626912545713,"gmtModify":1635224193844,"authorId":3586908956533728,"author":{"id":3586908956533728,"idStr":"3586908956533728","authorId":3586908956533728,"name":"一支升GoGo","avatar":"https://static.tigerbbs.com/e6ded53fb5327ba12901b0349ca92704","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":178234418,"type":1,"supId":0,"prevId":0,"content":"👍","text":"👍","html":"👍"}],"langContent":"EN"},{"id":178298016,"gmtCreate":1626822607635,"gmtModify":1631889838770,"author":{"id":"3586415957138494","authorId":"3586415957138494","name":"Kervin21","avatar":"https://static.tigerbbs.com/cb5cda809c6350e717fe7cd7d7789262","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3586415957138494","authorIdStr":"3586415957138494"},"htmlText":"Like and comment pls","listText":"Like and comment pls","text":"Like and comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/178298016","repostId":1199016731,"repostType":4,"repost":{"id":"1199016731","kind":"news","pubTimestamp":1626790980,"share":"https://www.laohu8.com/m/news/1199016731?lang=zh_CN&edition=full","pubTime":"2021-07-20 22:23","market":"us","language":"en","title":"Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1199016731","media":"Motley Fool","summary":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and p","content":" The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-07-20 22:23\n\n</h4>\n</header>\n<article>\n The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","CVAC":"CureVac B.V.","MRK":"默沙东","AZN":"阿斯利康","JNJ":"强生","MRNA":"Moderna, Inc.","SNY":"赛诺菲安万特","NVAX":"诺瓦瓦克斯医药","GSK":"葛兰素史克","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199016731","content_text":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.\n\n(July 20) Coronavirus Stocks Are Zooming Higher Today.\n\nSo what\nThe key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.\nSo the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.\nNow what\nIf the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.\nNovavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.","news_type":1,"symbols_score_info":{"PFE":0.9,"NVAX":0.9,"MRK":0.9,"BNTX":0.9,"AZN":0.9,"MRNA":0.9,"GSK":0.9,"SNY":0.9,"CVAC":0.9,"JNJ":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5276651,"gmtCreate":1626822809687,"gmtModify":1635225030202,"authorId":3567307840510045,"author":{"id":3567307840510045,"idStr":"3567307840510045","authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":178298016,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."},{"id":5276842,"gmtCreate":1626823418909,"gmtModify":1635225012277,"authorId":3586415957138494,"author":{"id":3586415957138494,"idStr":"3586415957138494","authorId":3586415957138494,"name":"Kervin21","avatar":"https://static.tigerbbs.com/cb5cda809c6350e717fe7cd7d7789262","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":178298016,"type":1,"supId":5276651,"prevId":0,"content":"👍🏻","text":"👍🏻","html":"👍🏻"},{"id":5276939,"gmtCreate":1626823778425,"gmtModify":1635225002992,"authorId":3573341177962944,"author":{"id":3573341177962944,"idStr":"3573341177962944","authorId":3573341177962944,"name":"buckethead","avatar":"https://static.tigerbbs.com/fb0baba9e10b75fa4dc0ff143e54bbea","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":178298016,"type":1,"supId":0,"prevId":0,"content":"ok done","text":"ok done","html":"ok done"}],"langContent":"EN"},{"id":178299028,"gmtCreate":1626822422364,"gmtModify":1626822422364,"author":{"id":"3585043179154199","authorId":"3585043179154199","name":"jacksoncheng","avatar":"https://static.tigerbbs.com/15cea2a12fcc802fa3161c7165a892de","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3585043179154199","authorIdStr":"3585043179154199"},"htmlText":"Yeah, it is ridiculous to see moderna getting new high","listText":"Yeah, it is ridiculous to see moderna getting new high","text":"Yeah, it is ridiculous to see moderna getting new high","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/178299028","repostId":1199016731,"repostType":4,"repost":{"id":"1199016731","kind":"news","pubTimestamp":1626790980,"share":"https://www.laohu8.com/m/news/1199016731?lang=zh_CN&edition=full","pubTime":"2021-07-20 22:23","market":"us","language":"en","title":"Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1199016731","media":"Motley Fool","summary":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and p","content":" The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-07-20 22:23\n\n</h4>\n</header>\n<article>\n The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","CVAC":"CureVac B.V.","MRK":"默沙东","AZN":"阿斯利康","JNJ":"强生","MRNA":"Moderna, Inc.","SNY":"赛诺菲安万特","NVAX":"诺瓦瓦克斯医药","GSK":"葛兰素史克","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199016731","content_text":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.\n\n(July 20) Coronavirus Stocks Are Zooming Higher Today.\n\nSo what\nThe key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.\nSo the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.\nNow what\nIf the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.\nNovavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.","news_type":1,"symbols_score_info":{"PFE":0.9,"NVAX":0.9,"MRK":0.9,"BNTX":0.9,"AZN":0.9,"MRNA":0.9,"GSK":0.9,"SNY":0.9,"CVAC":0.9,"JNJ":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7108108,"gmtCreate":1640478798058,"gmtModify":1640478798150,"authorId":3585043179154199,"author":{"id":3585043179154199,"idStr":"3585043179154199","authorId":3585043179154199,"name":"jacksoncheng","avatar":"https://static.tigerbbs.com/15cea2a12fcc802fa3161c7165a892de","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":178299028,"type":1,"supId":5277135,"prevId":0,"content":"hhhh","text":"hhhh","html":"hhhh"},{"id":5277135,"gmtCreate":1626824678898,"gmtModify":1635224985289,"authorId":3581978054709801,"author":{"id":3581978054709801,"idStr":"3581978054709801","authorId":3581978054709801,"name":"Nickystonks","avatar":"https://static.tigerbbs.com/9ea10f153b0e264f05c7d19fcc08cdee","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":178299028,"type":1,"supId":0,"prevId":0,"content":"agree","text":"agree","html":"agree"},{"id":5311120,"gmtCreate":1627071918882,"gmtModify":1627071918882,"authorId":3585043179154199,"author":{"id":3585043179154199,"idStr":"3585043179154199","authorId":3585043179154199,"name":"jacksoncheng","avatar":"https://static.tigerbbs.com/15cea2a12fcc802fa3161c7165a892de","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":178299028,"type":1,"supId":5297676,"prevId":0,"content":"no way I don't like it","text":"no way I don't like it","html":"no way I don't like it"},{"id":5297676,"gmtCreate":1626984020071,"gmtModify":1626984020071,"authorId":3586198471249922,"author":{"id":3586198471249922,"idStr":"3586198471249922","authorId":3586198471249922,"name":"EmmaS","avatar":"https://static.tigerbbs.com/41fa8b7739afa8f029d077d18c6201ab","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":178299028,"type":1,"supId":0,"prevId":0,"content":"you sold it?:P","text":"you sold it?:P","html":"you sold it?:P"}],"langContent":"EN"},{"id":178204390,"gmtCreate":1626822313610,"gmtModify":1633770794913,"author":{"id":"3569357432940876","authorId":"3569357432940876","name":"EeHoe","avatar":"https://static.tigerbbs.com/cb0c6bece08ddb8d0b70306a6488c1a2","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3569357432940876","authorIdStr":"3569357432940876"},"htmlText":"hopefully will covid will&nbsp;pass soon.&nbsp;","listText":"hopefully will covid will&nbsp;pass soon.&nbsp;","text":"hopefully will covid will pass soon.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/178204390","repostId":1199016731,"repostType":4,"repost":{"id":"1199016731","kind":"news","pubTimestamp":1626790980,"share":"https://www.laohu8.com/m/news/1199016731?lang=zh_CN&edition=full","pubTime":"2021-07-20 22:23","market":"us","language":"en","title":"Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1199016731","media":"Motley Fool","summary":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and p","content":" The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-07-20 22:23\n\n</h4>\n</header>\n<article>\n The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","CVAC":"CureVac B.V.","MRK":"默沙东","AZN":"阿斯利康","JNJ":"强生","MRNA":"Moderna, Inc.","SNY":"赛诺菲安万特","NVAX":"诺瓦瓦克斯医药","GSK":"葛兰素史克","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199016731","content_text":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.\n\n(July 20) Coronavirus Stocks Are Zooming Higher Today.\n\nSo what\nThe key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.\nSo the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.\nNow what\nIf the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.\nNovavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.","news_type":1,"symbols_score_info":{"PFE":0.9,"NVAX":0.9,"MRK":0.9,"BNTX":0.9,"AZN":0.9,"MRNA":0.9,"GSK":0.9,"SNY":0.9,"CVAC":0.9,"JNJ":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5281398,"gmtCreate":1626855823149,"gmtModify":1635224641399,"authorId":3581741175905126,"author":{"id":3581741175905126,"idStr":"3581741175905126","authorId":3581741175905126,"name":"sk5735","avatar":"https://static.tigerbbs.com/119fc82bddd3291f8c7e303167676732","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":178204390,"type":1,"supId":0,"prevId":0,"content":"Yup :(","text":"Yup :(","html":"Yup :("}],"langContent":"EN"},{"id":178201813,"gmtCreate":1626822011332,"gmtModify":1633770798733,"author":{"id":"3576260758860416","authorId":"3576260758860416","name":"andrew123","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3576260758860416","authorIdStr":"3576260758860416"},"htmlText":"Looks like tourism sector stk will&nbsp; be in&nbsp; for a hard time for recovery. Like n comment","listText":"Looks like tourism sector stk will&nbsp; be in&nbsp; for a hard time for recovery. Like n comment","text":"Looks like tourism sector stk will be in for a hard time for recovery. Like n comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/178201813","repostId":1199016731,"repostType":4,"repost":{"id":"1199016731","kind":"news","pubTimestamp":1626790980,"share":"https://www.laohu8.com/m/news/1199016731?lang=zh_CN&edition=full","pubTime":"2021-07-20 22:23","market":"us","language":"en","title":"Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1199016731","media":"Motley Fool","summary":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and p","content":" The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-07-20 22:23\n\n</h4>\n</header>\n<article>\n The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","CVAC":"CureVac B.V.","MRK":"默沙东","AZN":"阿斯利康","JNJ":"强生","MRNA":"Moderna, Inc.","SNY":"赛诺菲安万特","NVAX":"诺瓦瓦克斯医药","GSK":"葛兰素史克","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199016731","content_text":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.\n\n(July 20) Coronavirus Stocks Are Zooming Higher Today.\n\nSo what\nThe key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.\nSo the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.\nNow what\nIf the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.\nNovavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.","news_type":1,"symbols_score_info":{"PFE":0.9,"NVAX":0.9,"MRK":0.9,"BNTX":0.9,"AZN":0.9,"MRNA":0.9,"GSK":0.9,"SNY":0.9,"CVAC":0.9,"JNJ":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5276543,"gmtCreate":1626822294660,"gmtModify":1635225039932,"authorId":3569357432940876,"author":{"id":3569357432940876,"idStr":"3569357432940876","authorId":3569357432940876,"name":"EeHoe","avatar":"https://static.tigerbbs.com/cb0c6bece08ddb8d0b70306a6488c1a2","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":178201813,"type":1,"supId":0,"prevId":0,"content":"yaa","text":"yaa","html":"yaa"},{"id":5276669,"gmtCreate":1626822867145,"gmtModify":1635225028574,"authorId":3567307840510045,"author":{"id":3567307840510045,"idStr":"3567307840510045","authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":178201813,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."},{"id":5276817,"gmtCreate":1626823352972,"gmtModify":1635225014861,"authorId":3576260758860416,"author":{"id":3576260758860416,"idStr":"3576260758860416","authorId":3576260758860416,"name":"andrew123","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":178201813,"type":1,"supId":5276669,"prevId":0,"content":"done","text":"done","html":"done"},{"id":5291520,"gmtCreate":1626935946227,"gmtModify":1635223911864,"authorId":3586990023332519,"author":{"id":3586990023332519,"idStr":"3586990023332519","authorId":3586990023332519,"name":"StarGate","avatar":"https://static.tigerbbs.com/9db084b2eae373a6cc56043329defb07","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":178201813,"type":1,"supId":0,"prevId":0,"content":"looking at current situation, travel might be allowed in 2023 middle of the year or earlier...stay safe","text":"looking at current situation, travel might be allowed in 2023 middle of the year or earlier...stay safe","html":"looking at current situation, travel might be allowed in 2023 middle of the year or earlier...stay safe"}],"langContent":"EN"},{"id":178209757,"gmtCreate":1626821902979,"gmtModify":1633770799872,"author":{"id":"3581919183376534","authorId":"3581919183376534","name":"Huatkor","avatar":"https://static.tigerbbs.com/6f3897aace055b5fa9f58089c1e880d8","vip":1,"crmLevel":12,"crmLevelSwitch":0,"idStr":"3581919183376534","authorIdStr":"3581919183376534"},"htmlText":"If the current vaccine can offer sufficient protection against the variants then their price shouldn’t surge so much.&nbsp;","listText":"If the current vaccine can offer sufficient protection against the variants then their price shouldn’t surge so much.&nbsp;","text":"If the current vaccine can offer sufficient protection against the variants then their price shouldn’t surge so much.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/178209757","repostId":1199016731,"repostType":4,"repost":{"id":"1199016731","kind":"news","pubTimestamp":1626790980,"share":"https://www.laohu8.com/m/news/1199016731?lang=zh_CN&edition=full","pubTime":"2021-07-20 22:23","market":"us","language":"en","title":"Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1199016731","media":"Motley Fool","summary":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and p","content":" The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-07-20 22:23\n\n</h4>\n</header>\n<article>\n The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","CVAC":"CureVac B.V.","MRK":"默沙东","AZN":"阿斯利康","JNJ":"强生","MRNA":"Moderna, Inc.","SNY":"赛诺菲安万特","NVAX":"诺瓦瓦克斯医药","GSK":"葛兰素史克","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199016731","content_text":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.\n\n(July 20) Coronavirus Stocks Are Zooming Higher Today.\n\nSo what\nThe key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.\nSo the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.\nNow what\nIf the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.\nNovavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.","news_type":1,"symbols_score_info":{"PFE":0.9,"NVAX":0.9,"MRK":0.9,"BNTX":0.9,"AZN":0.9,"MRNA":0.9,"GSK":0.9,"SNY":0.9,"CVAC":0.9,"JNJ":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":178673752,"gmtCreate":1626821310876,"gmtModify":1633770807706,"author":{"id":"3580638845558081","authorId":"3580638845558081","name":"在於我們是","avatar":"https://static.tigerbbs.com/400933d41d715fa2dc89a42f82e63f64","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3580638845558081","authorIdStr":"3580638845558081"},"htmlText":"Please like and comment [Grin]&nbsp;","listText":"Please like and comment [Grin]&nbsp;","text":"Please like and comment [Grin]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/178673752","repostId":1199016731,"repostType":4,"repost":{"id":"1199016731","kind":"news","pubTimestamp":1626790980,"share":"https://www.laohu8.com/m/news/1199016731?lang=zh_CN&edition=full","pubTime":"2021-07-20 22:23","market":"us","language":"en","title":"Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1199016731","media":"Motley Fool","summary":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and p","content":" The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-07-20 22:23\n\n</h4>\n</header>\n<article>\n The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","CVAC":"CureVac B.V.","MRK":"默沙东","AZN":"阿斯利康","JNJ":"强生","MRNA":"Moderna, Inc.","SNY":"赛诺菲安万特","NVAX":"诺瓦瓦克斯医药","GSK":"葛兰素史克","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199016731","content_text":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.\n\n(July 20) Coronavirus Stocks Are Zooming Higher Today.\n\nSo what\nThe key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.\nSo the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.\nNow what\nIf the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.\nNovavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.","news_type":1,"symbols_score_info":{"PFE":0.9,"NVAX":0.9,"MRK":0.9,"BNTX":0.9,"AZN":0.9,"MRNA":0.9,"GSK":0.9,"SNY":0.9,"CVAC":0.9,"JNJ":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5276489,"gmtCreate":1626822055006,"gmtModify":1635225044384,"authorId":3576260758860416,"author":{"id":3576260758860416,"idStr":"3576260758860416","authorId":3576260758860416,"name":"andrew123","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":178673752,"type":1,"supId":0,"prevId":0,"content":"like yrs u like mine.ok","text":"like yrs u like mine.ok","html":"like yrs u like mine.ok"},{"id":5276671,"gmtCreate":1626822882886,"gmtModify":1635225028466,"authorId":3567307840510045,"author":{"id":3567307840510045,"idStr":"3567307840510045","authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":178673752,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."}],"langContent":"EN"},{"id":178643135,"gmtCreate":1626820608727,"gmtModify":1633770818212,"author":{"id":"3583060399914185","authorId":"3583060399914185","name":"Terc","avatar":"https://static.tigerbbs.com/030a47b34f2b276e172016715b3148e0","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3583060399914185","authorIdStr":"3583060399914185"},"htmlText":"Let's see","listText":"Let's see","text":"Let's see","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/178643135","repostId":1199016731,"repostType":4,"repost":{"id":"1199016731","kind":"news","pubTimestamp":1626790980,"share":"https://www.laohu8.com/m/news/1199016731?lang=zh_CN&edition=full","pubTime":"2021-07-20 22:23","market":"us","language":"en","title":"Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1199016731","media":"Motley Fool","summary":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and p","content":" The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-07-20 22:23\n\n</h4>\n</header>\n<article>\n The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","CVAC":"CureVac B.V.","MRK":"默沙东","AZN":"阿斯利康","JNJ":"强生","MRNA":"Moderna, Inc.","SNY":"赛诺菲安万特","NVAX":"诺瓦瓦克斯医药","GSK":"葛兰素史克","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199016731","content_text":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.\n\n(July 20) Coronavirus Stocks Are Zooming Higher Today.\n\nSo what\nThe key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.\nSo the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.\nNow what\nIf the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.\nNovavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.","news_type":1,"symbols_score_info":{"PFE":0.9,"NVAX":0.9,"MRK":0.9,"BNTX":0.9,"AZN":0.9,"MRNA":0.9,"GSK":0.9,"SNY":0.9,"CVAC":0.9,"JNJ":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":178643310,"gmtCreate":1626820607930,"gmtModify":1633770818333,"author":{"id":"4088052587339740","authorId":"4088052587339740","name":"YKYANG","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4088052587339740","authorIdStr":"4088052587339740"},"htmlText":"Good to buy&nbsp;","listText":"Good to buy&nbsp;","text":"Good to buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/178643310","repostId":1199016731,"repostType":4,"repost":{"id":"1199016731","kind":"news","pubTimestamp":1626790980,"share":"https://www.laohu8.com/m/news/1199016731?lang=zh_CN&edition=full","pubTime":"2021-07-20 22:23","market":"us","language":"en","title":"Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1199016731","media":"Motley Fool","summary":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and p","content":" The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-07-20 22:23\n\n</h4>\n</header>\n<article>\n The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","CVAC":"CureVac B.V.","MRK":"默沙东","AZN":"阿斯利康","JNJ":"强生","MRNA":"Moderna, Inc.","SNY":"赛诺菲安万特","NVAX":"诺瓦瓦克斯医药","GSK":"葛兰素史克","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199016731","content_text":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.\n\n(July 20) Coronavirus Stocks Are Zooming Higher Today.\n\nSo what\nThe key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.\nSo the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.\nNow what\nIf the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.\nNovavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.","news_type":1,"symbols_score_info":{"PFE":0.9,"NVAX":0.9,"MRK":0.9,"BNTX":0.9,"AZN":0.9,"MRNA":0.9,"GSK":0.9,"SNY":0.9,"CVAC":0.9,"JNJ":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":178653806,"gmtCreate":1626819864605,"gmtModify":1626819864605,"author":{"id":"3559581955535845","authorId":"3559581955535845","name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3559581955535845","authorIdStr":"3559581955535845"},"htmlText":"I shall put on watch list.&nbsp;","listText":"I shall put on watch list.&nbsp;","text":"I shall put on watch list.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":19,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/178653806","repostId":1199016731,"repostType":4,"repost":{"id":"1199016731","kind":"news","pubTimestamp":1626790980,"share":"https://www.laohu8.com/m/news/1199016731?lang=zh_CN&edition=full","pubTime":"2021-07-20 22:23","market":"us","language":"en","title":"Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1199016731","media":"Motley Fool","summary":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and p","content":" The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-07-20 22:23\n\n</h4>\n</header>\n<article>\n The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","CVAC":"CureVac B.V.","MRK":"默沙东","AZN":"阿斯利康","JNJ":"强生","MRNA":"Moderna, Inc.","SNY":"赛诺菲安万特","NVAX":"诺瓦瓦克斯医药","GSK":"葛兰素史克","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199016731","content_text":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.\n\n(July 20) Coronavirus Stocks Are Zooming Higher Today.\n\nSo what\nThe key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.\nSo the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.\nNow what\nIf the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.\nNovavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.","news_type":1,"symbols_score_info":{"PFE":0.9,"NVAX":0.9,"MRK":0.9,"BNTX":0.9,"AZN":0.9,"MRNA":0.9,"GSK":0.9,"SNY":0.9,"CVAC":0.9,"JNJ":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5277352,"gmtCreate":1626825576754,"gmtModify":1635224964727,"authorId":4087351235415740,"author":{"id":4087351235415740,"idStr":"4087351235415740","authorId":4087351235415740,"name":"4e6e78ce","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":178653806,"type":1,"supId":0,"prevId":0,"content":"all the best!","text":"all the best!","html":"all the best!"},{"id":5279276,"gmtCreate":1626835730304,"gmtModify":1635224798937,"authorId":3563664364598207,"author":{"id":3563664364598207,"idStr":"3563664364598207","authorId":3563664364598207,"name":"56a3dd2f","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":178653806,"type":1,"supId":0,"prevId":0,"content":"😊👍","text":"😊👍","html":"😊👍"},{"id":5280147,"gmtCreate":1626843175090,"gmtModify":1635224731654,"authorId":3559581955535845,"author":{"id":3559581955535845,"idStr":"3559581955535845","authorId":3559581955535845,"name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":178653806,"type":1,"supId":5279276,"prevId":0,"content":"Thanks","text":"Thanks","html":"Thanks"},{"id":5280150,"gmtCreate":1626843203455,"gmtModify":1635224731328,"authorId":3559581955535845,"author":{"id":3559581955535845,"idStr":"3559581955535845","authorId":3559581955535845,"name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":178653806,"type":1,"supId":5277352,"prevId":0,"content":"All the best to you too!","text":"All the best to you too!","html":"All the best to you too!"}],"langContent":"EN"},{"id":178683131,"gmtCreate":1626817081623,"gmtModify":1631889014272,"author":{"id":"3562564487802138","authorId":"3562564487802138","name":"飞天神鼠","avatar":"https://static.tigerbbs.com/d7b258e8e42a780bde477c48b8767f73","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3562564487802138","authorIdStr":"3562564487802138"},"htmlText":"[财迷]&nbsp;[财迷]&nbsp;","listText":"[财迷]&nbsp;[财迷]&nbsp;","text":"[财迷] [财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/178683131","repostId":1199016731,"repostType":4,"repost":{"id":"1199016731","kind":"news","pubTimestamp":1626790980,"share":"https://www.laohu8.com/m/news/1199016731?lang=zh_CN&edition=full","pubTime":"2021-07-20 22:23","market":"us","language":"en","title":"Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1199016731","media":"Motley Fool","summary":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and p","content":" The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-07-20 22:23\n\n</h4>\n</header>\n<article>\n The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","CVAC":"CureVac B.V.","MRK":"默沙东","AZN":"阿斯利康","JNJ":"强生","MRNA":"Moderna, Inc.","SNY":"赛诺菲安万特","NVAX":"诺瓦瓦克斯医药","GSK":"葛兰素史克","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199016731","content_text":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.\n\n(July 20) Coronavirus Stocks Are Zooming Higher Today.\n\nSo what\nThe key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.\nSo the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.\nNow what\nIf the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.\nNovavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.","news_type":1,"symbols_score_info":{"PFE":0.9,"NVAX":0.9,"MRK":0.9,"BNTX":0.9,"AZN":0.9,"MRNA":0.9,"GSK":0.9,"SNY":0.9,"CVAC":0.9,"JNJ":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":178616573,"gmtCreate":1626816120492,"gmtModify":1633770857890,"author":{"id":"3582922989777578","authorId":"3582922989777578","name":"SPOT_ON","avatar":"https://static.tigerbbs.com/080f029371339d9db26930961de6adb1","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3582922989777578","authorIdStr":"3582922989777578"},"htmlText":"Like n follow&nbsp;","listText":"Like n follow&nbsp;","text":"Like n follow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/178616573","repostId":1199016731,"repostType":4,"repost":{"id":"1199016731","kind":"news","pubTimestamp":1626790980,"share":"https://www.laohu8.com/m/news/1199016731?lang=zh_CN&edition=full","pubTime":"2021-07-20 22:23","market":"us","language":"en","title":"Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1199016731","media":"Motley Fool","summary":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and p","content":" The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-07-20 22:23\n\n</h4>\n</header>\n<article>\n The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","CVAC":"CureVac B.V.","MRK":"默沙东","AZN":"阿斯利康","JNJ":"强生","MRNA":"Moderna, Inc.","SNY":"赛诺菲安万特","NVAX":"诺瓦瓦克斯医药","GSK":"葛兰素史克","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199016731","content_text":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.\n\n(July 20) Coronavirus Stocks Are Zooming Higher Today.\n\nSo what\nThe key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.\nSo the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.\nNow what\nIf the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.\nNovavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.","news_type":1,"symbols_score_info":{"PFE":0.9,"NVAX":0.9,"MRK":0.9,"BNTX":0.9,"AZN":0.9,"MRNA":0.9,"GSK":0.9,"SNY":0.9,"CVAC":0.9,"JNJ":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5276673,"gmtCreate":1626822903218,"gmtModify":1635225028249,"authorId":3567307840510045,"author":{"id":3567307840510045,"idStr":"3567307840510045","authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":178616573,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."}],"langContent":"EN"},{"id":178876832,"gmtCreate":1626803235226,"gmtModify":1633770882165,"author":{"id":"3578582505944448","authorId":"3578582505944448","name":"KevinToh","avatar":"https://static.tigerbbs.com/6996c5e2d4215d4f5babe8f7a9eebbff","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3578582505944448","authorIdStr":"3578582505944448"},"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/178876832","repostId":1199016731,"repostType":4,"repost":{"id":"1199016731","kind":"news","pubTimestamp":1626790980,"share":"https://www.laohu8.com/m/news/1199016731?lang=zh_CN&edition=full","pubTime":"2021-07-20 22:23","market":"us","language":"en","title":"Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1199016731","media":"Motley Fool","summary":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and p","content":" The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-07-20 22:23\n\n</h4>\n</header>\n<article>\n The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","CVAC":"CureVac B.V.","MRK":"默沙东","AZN":"阿斯利康","JNJ":"强生","MRNA":"Moderna, Inc.","SNY":"赛诺菲安万特","NVAX":"诺瓦瓦克斯医药","GSK":"葛兰素史克","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199016731","content_text":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.\n\n(July 20) Coronavirus Stocks Are Zooming Higher Today.\n\nSo what\nThe key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.\nSo the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.\nNow what\nIf the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.\nNovavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.","news_type":1,"symbols_score_info":{"PFE":0.9,"NVAX":0.9,"MRK":0.9,"BNTX":0.9,"AZN":0.9,"MRNA":0.9,"GSK":0.9,"SNY":0.9,"CVAC":0.9,"JNJ":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":178864431,"gmtCreate":1626798285923,"gmtModify":1633770905021,"author":{"id":"4089720653683940","authorId":"4089720653683940","name":"7a1f5064","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4089720653683940","authorIdStr":"4089720653683940"},"htmlText":"All pharma going up","listText":"All pharma going up","text":"All pharma going up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/178864431","repostId":1199016731,"repostType":4,"repost":{"id":"1199016731","kind":"news","pubTimestamp":1626790980,"share":"https://www.laohu8.com/m/news/1199016731?lang=zh_CN&edition=full","pubTime":"2021-07-20 22:23","market":"us","language":"en","title":"Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1199016731","media":"Motley Fool","summary":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and p","content":" The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoronavirus Stocks Are Zooming Higher Today<blockquote>冠状病毒股票今天飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-07-20 22:23\n\n</h4>\n</header>\n<article>\n The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. (July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.<blockquote>病例和死亡人数的激增可能会显着增加对这些公司现有和管道产品的需求。（7月20日）冠状病毒股票今天飙升。</blockquote> <img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> So what<blockquote>那又怎样</blockquote> The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.<blockquote>这些增加的关键原因很简单：由于其强大的德尔塔变异毒株，冠状病毒再次呈上升趋势。根据纽约时报周日的数据显示，美国14天内新增病例的变化令人担忧地增加了140%，死亡人数增加了33%。</blockquote> So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.<blockquote>因此，更努力、更广泛地推广疫苗的必要性是显而易见的；此举显然对Moderna和BioNTech都有利。这些公司（包括BioNTech partner（辉瑞）提供食品和药物管理局授权的仅有的三种冠状病毒疫苗中的两种。它还应该有助于Co-Diagnostics，这是一家备受瞩目的COVID-19检测产品制造商。</blockquote> Now what<blockquote>现在怎么办</blockquote> If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.<blockquote>如果冠状病毒继续激增，我们很可能会面临疫苗“全力以赴”的局面。也许专注于疫苗的生物技术公司Novavax和Vaxart正在开发的药物将获得FDA的授权。</blockquote> Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.<blockquote>Novavax计划本季度为其SNVX-CoV2373申请紧急使用授权，而Vaxart肯定会因其目前正在开发的口服疫苗而受到投资者的关注——尽管该计划引起了争议。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","CVAC":"CureVac B.V.","MRK":"默沙东","AZN":"阿斯利康","JNJ":"强生","MRNA":"Moderna, Inc.","SNY":"赛诺菲安万特","NVAX":"诺瓦瓦克斯医药","GSK":"葛兰素史克","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199016731","content_text":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.\n\n(July 20) Coronavirus Stocks Are Zooming Higher Today.\n\nSo what\nThe key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.\nSo the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.\nNow what\nIf the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.\nNovavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.","news_type":1,"symbols_score_info":{"PFE":0.9,"NVAX":0.9,"MRK":0.9,"BNTX":0.9,"AZN":0.9,"MRNA":0.9,"GSK":0.9,"SNY":0.9,"CVAC":0.9,"JNJ":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":302,"commentSize":58,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}